Health Canada Approves ZOLADEX® LA for the Management of Estrogen Receptor-Positive (ER+) Early Breast Cancer with a ...
MARKHAM, Ontario — TerSera Canada Inc. today announced that Health Canada has approved a supplemental New Drug Submission for ZOLADEX LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer …